Data Insights

Tenalisib by Rhizen Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Tenalisib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Tenalisib in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Tenalisib in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Tenalisib in Diffuse Large B-Cell Lymphoma

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Tenalisib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

RP-7214 by Rhizen Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

RP-7214 is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Data Insights

Tenalisib by Rhizen Pharmaceuticals for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Breast Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Breast Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Ovarian Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Colorectal Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Colorectal Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Pancreatic Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Gastric Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Gastric Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Small-Cell Lung Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Small-Cell Lung Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Solid Tumor: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Solid Tumor

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Endometrial Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Fallopian Tube Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Fallopian Tube Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Peritoneal Cancer: Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Peritoneal Cancer

Data Insights

RP-12146 by Rhizen Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)